Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens

Nature Biotechnology

Volumn 30, Issue 9, 2012, Pages 883-888

  Wegmann, Frank ^a   Gartlan, Kate H ^a   Harandi, Ali M ^b   Brinckmann, Sarah A ^a   Coccia, Margherita ^a   Hillson, William R ^a   Kok, Wai Ling ^c   Cole, Suzanne ^c   Ho, Ling Pei ^c   Lambe, Teresa ^d   Puthia, Manoj ^e   Svanborg, Catharina ^e   Scherer, Erin M ^f   Krashias, George ^a   Williams, Adam ^g   Blattman, Joseph N ^f   Greenberg, Philip D ^f   Flavell, Richard A ^g   Moghaddam, Amin E ^a   Sheppard, Neil C ^a,h   Sattentau, Quentin J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF WASHINGTON   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELLS; CYTOKINE RESPONSE; DENDRITIC CELLS; DNA VACCINE; DOUBLE STRANDED DNA; HERPES SIMPLEX VIRUS TYPE-2; HUMAN USE; IN-VITRO; IN-VIVO; INTRANASAL; LYMPH NODE; NANOSCALE COMPLEXES; POLYCATIONS; POLYETHYLENEIMINE; TRANSFECTION REAGENTS;

GLYCOPROTEINS; NUCLEIC ACIDS; VACCINES; VIRUSES;

ANTIGENS;

CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; GLYCOPROTEIN D; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INITIATION FACTOR 3; POLYETHYLENEIMINE; POLYGLACTIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ARTICLE; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DENDRITIC CELL; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A H1N1; LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIGENS, VIRAL; BODY WEIGHT; CELL LINE; DNA; FEMALE; HEMAGGLUTININS, VIRAL; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; NASAL MUCOSA; ORTHOMYXOVIRIDAE INFECTIONS; POLYETHYLENEIMINE; STATISTICS, NONPARAMETRIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

HUMAN HERPESVIRUS 2;

EID: 84866103085     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2344     Document Type: Article

References (39)

1. Chen, K. & Cerutti, A. Vaccination strategies to promote mucosal antibody responses. Immunity 33, 479-491 (2010).
2. Gunther, M. et al. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 77, 438-439 (2011).
3. Lungwitz, U., Breunig, M., Blunk, T. & Gopferich, A. Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60, 247-266 (2005). (Pubitemid 40804565)
4. Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592-605 (2012).
5. Fujihashi, K., Koga, T., van Ginkel, F.W., Hagiwara, Y. & McGhee, J.R. A dilemma for mucosal vaccination: effcacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431-2438 (2002). (Pubitemid 34615580)
6. Lewis, D.J. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxifed mutant of Escherichia coli heat labile toxin. PLoS ONE 4, e6999 (2009).
7. Sogaard, O.S. et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin. Infect. Dis. 51, 42-50 (2010).
8. Heikenwalder, M. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10, 187-192 (2004). (Pubitemid 38524890)
9. Kasturi, S.P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
10. De Gregorio, E., D'Oro, U. & Wack, A. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 21, 339-345 (2009).
11. Lambrecht, B.N., Kool, M., Willart, M.A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29 (2009).
12. Gavin, A.L. et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936-1938 (2006). (Pubitemid 46026117)
13. Hu, K. et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 29, 1455-1462 (2011).
14. Ma, Y.F. & Yang, Y.W. Delivery of DNA-based cancer vaccine with polyethylenimine. Eur. J. Pharm. Sci. 40, 75-83 (2010).
15. Orr, G. et al. Syndecan-1 mediates the coupling of positively charged submicrometer amorphous silica particles with actin flaments across the alveolar epithelial cell membrane. Toxicol. Appl. Pharmacol. 236, 210-220 (2009).
16. Wegrowski, Y. et al. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin. Exp. Immunol. 144, 485-493 (2006). (Pubitemid 43799932)
17. Park, K. Luciferin liposomes for enhanced in vivo bioluminescence. J. Control. Release 141, 109 (2009).
18. Hunter, A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 58, 1523-1531 (2006). (Pubitemid 44820504)
19. Mutsch, M. et al. Use of the inactivated intranasal infuenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004). (Pubitemid 38252537)
20. Yamamoto, S. et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94, 5267-5272 (1997). (Pubitemid 27214772)
21. Lee, J.B., Jang, J.E., Song, M.K. & Chang, J. Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens. PLoS One 4, e5190 (2009).
22. Lindqvist, M., Persson, J., Thorn, K. & Harandi, A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182, 6435-6443 (2009).
23. Kong, L. et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J. Mol. Biol. 403, 131-147 (2010).
24. Rudolph, C. et al. Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application. J. Gene Med. 7, 59-66 (2005).
25. Chen, J. et al. Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int. J. Nanomedicine 6, 77-84 (2011).
26. Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812-1823 (2011).
27. Manicassamy, S. & Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 21, 185-193 (2009).
28. Marichal, T. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17, 996-1002 (2011).
29. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S. & Flavell, R.A. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008). (Pubitemid 351871731)
30. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 infammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
31. Torrieri-Dramard, L. et al. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against infuenza viruses. Mol. Ther. 19, 602-611 (2011).
32. Littman, D.R. & Rudensky, A.Y. Th17 and regulatory T cells in mediating and restraining infammation. Cell 140, 845-858 (2010).
33. Wegmann, F. et al. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-infammatory environment. PLoS ONE 6, e15861 (2011).
34. Skehel, J.J. & Waterfeld, M.D. Studies on the primary structure of the infuenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 72, 93-97 (1975).
35. Del Campo, J. et al. Intranasal immunization with a proteoliposome- derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 28, 1193-1200 (2010).
36. Sutterwala, F.S. et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317-327 (2006).
37. Krashias, G. et al. Potent adaptive immune responses induced against HIV-1 gp140 and infuenza virus HA by a polyanionic carbomer. Vaccine 28, 2482-2489 (2010).
38. Gomez Roman, V.R. et al. Development of standard operating procedures to obtain longitudinal vaginal specimens from nulliparous rabbits as part of HIV vaccine mucosal immunogenicity studies. J. Immunol. Methods 363, 29-41 (2010).
39. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).